Gracell Biotechnologies to Participate in Truist Securities Cell Therapy Symposium
20 juin 2023 08h30 HE
|
Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU and SHANGHAI, China, June 20, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company...
Gracell Biotechnologies Presents Longer-Term Results for FasTCAR-T GC012F in B-Cell Non-Hodgkin’s Lymphoma at EHA2023, Highlighting 100% Overall Response Rate
10 juin 2023 10h30 HE
|
Gracell Biotechnologies Inc.
Data on CD19/BCMA dual-targeting FasTCAR-T GC012F showed 100% overall response rate (ORR) and 66.7% 6-month complete response (CR) rate among treated patients, all with diffuse large B-cell lymphoma...
EHA2023 | 亘喜生物公布FasTCAR-T GC012F治疗B-NHL的最新临床研究成果，总体应答率高达100%
10 juin 2023 10h30 HE
|
Gracell Biotechnologies Inc.
CD19/BCMA双靶点FasTCAR-T GC012F展现优异疗效数据：总体应答率（ORR）高达100%，在第6个月时的完全缓解率（CR）为67%，所有患者均为弥漫性大B细胞淋巴瘤（DLBCL）亚型患者 GC012F治疗复发/难治性多发性骨髓瘤（RRMM）以及供者来源CAR-T GC007g治疗B-ALL的临床数据已于6月9日在EHA2023年会上分别以学术海报形式公布 ...
Gracell Biotechnologies to Participate in Jefferies Healthcare Conference
24 mai 2023 16h01 HE
|
Gracell Biotechnologies Inc.
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, May 24, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical...
Gracell Biotechnologies to Host KOL Webinar on Multiple Myeloma on May 22nd
15 mai 2023 09h15 HE
|
Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 15, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated...
Gracell Biotechnologies Reports First Quarter 2023 Unaudited Financial Results, and Provides Corporate Update
15 mai 2023 07h00 HE
|
Gracell Biotechnologies Inc.
Presenting longer-term follow-up data from investigator-initiated trial (IIT) evaluating BCMA/CD19 dual-targeting FasTCAR-T GC012F in relapsed/refractory multiple myeloma (RRMM) at 2023 ASCO and...
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
10 mai 2023 16h19 HE
|
Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 10, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated...
Gracell Biotechnologies to Report First Quarter 2023 Financials on Monday, May 15, 2023
02 mai 2023 16h00 HE
|
Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 02, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated...
Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022
25 avr. 2023 16h13 HE
|
Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, April 25, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company...
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
22 mars 2023 16h10 HE
|
Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, March 22, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical...